ライフサイエンスコーパス: serglycin

1 und to the glycosaminoglycan (GAG) chains of serglycin.

2 fects of proteases that are complex-bound to serglycin.

3 ked to the chondroitin-sulfate proteoglycan, serglycin.

4 d with the chondroitin-sulfate proteoglycan, serglycin.

5 nogen activator was distributed similarly to serglycin.

6 Recently, it was discovered that serglycin, a hematopoietic cell proteoglycan, is the maj

7 Here we show that serglycin, a secretory granule proteoglycan of hematopoi

8 Serglycin acts as scaffold for packaging the positively

9 in granules along with other mediators using serglycin and its carried glycosaminoglycan side chains.

10 High levels of serglycin are present in the bone marrow aspirates of at

11 lacking mouse mast cell protease 6, a major serglycin-associated protease, exhibited similar defects

12 e mast cells underwent apoptotic cell death, serglycin(-/-) cells died predominantly by necrosis.

13 similar defects in apoptosis as observed in serglycin(-/-) cells, indicating that the pro-apoptotic

14 Targets exposed to double-labeled granzyme B-serglycin complexes show solely the uptake of granzyme B

15 molecular interaction of secreted granzyme B-serglycin complexes with target cells remains undefined.

16 The serglycin-containing vesicles in HUVECs are distinct fro

17 Recombinant serglycin core protein was used to generate an antibody

18 Tumors formed from cells deficient in serglycin exhibited diminished levels of hepatocyte grow

19 To investigate if serglycin expression has an impact on diet-induced adipo

20 the first intron may be related to the high serglycin expression in HL60 relative to HEL or CHRF cel

21 Co-precipitation of serglycin from conditioned medium of MM cells using a CD

22 derived perlecan heparan sulfate chains than serglycin GAG chains.

23 terations in chromatin structure may control serglycin gene expression.

24 We have compared regulation of the serglycin gene in human erythroleukemia (HEL) and CHRF 2

25 e DNase I-hypersensitive sites (DHSS) of the serglycin gene in resting and phorbol 12-myristate 13-ac

26 tudies establishing the nature of granzyme B-serglycin (GrB.SG) complex.

27 ry identified (i) the 25-kDa core protein as serglycin, (ii) the 90-kDa core protein as inter-alpha-i

28 vide direct evidence for a critical role for serglycin in MM pathogenesis and show that targeting ser

29 Together, these findings implicate serglycin in promoting apoptotic versus necrotic cell de

30 n together, this study introduces a role for serglycin in the regulation of obesity-induced adipose i

31 learn whether the physiologic effector, GrB-serglycin, initiates apoptosis primarily through caspase

32 Serglycin is a proteoglycan highly expressed by various

33 This study revealed that platelet serglycin is decorated with chondroitin/dermatan sulfate

34 ndicating that the pro-apoptotic function of serglycin is due to downstream effects of proteases that

35 smembrane domain, flow cytometry showed that serglycin is present on the MM cell surface, and attachm

36 It has been found that serglycin is synthesized by endothelial cells, is locali

37 Here, we show that serglycin knockdown (by approximately 85% compared with

38 LP2 and IalphaIHC2 with macrophages, whereas serglycin localizes to the underlying glycosaminoglycan-

39 ve high homology with the orthologous murine serglycin locus and are rich in potential transcription

40 e cytosol and that the necrotic phenotype of serglycin(-/-) mast cells was linked to defective degrad

41 Wild type and serglycin(-/-) mast cells were equally sensitive to a ra

42 evelopment of blood vessels, indicating that serglycin may affect tumor angiogenesis.

43 Serglycin may be important for the function of these ves

44 n in MM pathogenesis and show that targeting serglycin may provide a novel therapeutic approach for M

45 Serglycin messenger RNA in human umbilical vein endothel

46 how the interaction of granzyme B (GrB) with serglycin might influence the apoptotic potential of thi

47 PMA virtually eliminated expression of serglycin mRNA and promoter constructs, but dbcAMP incre

48 Finally, we demonstrate that serglycin mRNA expression in MM cells is up-regulated by

49 ee cells correlated with relative endogenous serglycin mRNA expression.

50 MC-(W(sash))-, serglycin-, NDST2-, and MCPT4-deficient extracts lacked

51 tain regulatory sequences derived from human serglycin, preproapolipoprotein C II, and Egr1 genes.

52 induce mBMMC to increase their expression of serglycin proteoglycan and carboxypeptidase A.

53 om participating in extracellular processes, serglycin proteoglycan and one of its associated proteas

54 including a single consensus sequence of the serglycin proteoglycan core protein bound heparin strong

55 Even though serglycin proteoglycan does not have a transmembrane dom

56 The stimulative effect on serglycin proteoglycan expression and the inhibitory eff

57 The serglycin proteoglycan is best known as a hematopoietic

58 A3 type that are electrostatically bound to serglycin proteoglycan.

59 low mMCP-9 to form multimeric complexes with serglycin proteoglycans and other negatively charged pro

60 Cs) can reversibly alter their expression of serglycin proteoglycans and the homologous granule chyma

61 diators such as bioactive amines, cytokines, serglycin proteoglycans with negatively charged glycosam

62 anule mediators (e.g., neutral proteases and serglycin proteoglycans) and proinflammatory cytokines (

63 (MCs) ionically bound to heparin-containing serglycin proteoglycans.

64 arin and/or chondroitin sulfate E containing serglycin proteoglycans.

65 s multimeric complexes with the proteoglycan serglycin (SG) in cytotoxic granules, and cytotoxic cell

66 Serglycin (SG), the hematopoietic cell secretory granule

67 Furthermore, knockdown of serglycin significantly decreased MM cell adhesion to bo

68 A granule-associated proteoglycan, namely serglycin, that contains chondroitin 4-sulfate (CS) glyc

69 ng electrostatic transfer of granzyme B from serglycin to cell surface proteins.

70 monstrates the exchange of the granzyme from serglycin to immobilized, sulfated glycosaminoglycans.

71 Furthermore, serglycin, tryptase, and carboxypeptidase A messenger RN

72 teolysis through a secretory granule-derived serglycin-tryptase axis as a novel principle for histone

73 reover, it was shown that the absence of the serglycin-tryptase axis resulted in altered chromatin co

74 tones as primary proteolytic targets for the serglycin-tryptase axis.

75 A core protein of the appropriate size for serglycin was detected by analysis of the chondroitinase

76 CD44 is the cell surface-binding partner for serglycin, which therefore may serve as a major ligand f